Previous Close | 1.1100 |
Open | 1.1100 |
Bid | 1.0600 x N/A |
Ask | 1.1100 x N/A |
Day's Range | 1.0700 - 1.1100 |
52 Week Range | 0.9300 - 7.7500 |
Volume | |
Avg. Volume | 18,125 |
Market Cap | 63.968M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8930 |
Earnings Date | Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.25 |
Plans to release financial results for its fiscal 2023 first quarter for the three-month period ended ...
TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, Aug
– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. – Field Trip Discovery to be renamed Reunion Neuroscience Inc., remaining listed on the NASDAQ Stock Market and Toronto Stock Exchange. TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) ("Field Trip", the "Company"), a global leader in the development and delivery of psychedelic therapies, is pleased to announc